Celyad Revenue and Competitors
Estimated Revenue & Valuation
- Celyad's estimated annual revenue is currently $75.8M per year.
- Celyad's estimated revenue per employee is $155,000
Employee Data
- Celyad has 489 Employees.
Celyad's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Head Intellectual Property | Reveal Email/Phone |
3 | General Counsel and Company Secretary | Reveal Email/Phone |
4 | Head Legal | Reveal Email/Phone |
5 | Director R&D | Reveal Email/Phone |
6 | QA CSV | Reveal Email/Phone |
7 | Senior Production Technician | Reveal Email/Phone |
8 | R&D Senior Scientist | Reveal Email/Phone |
9 | Sr Clinical Research Associate | Reveal Email/Phone |
10 | Senior Production Technician | Reveal Email/Phone |
Celyad Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.6M | 4 | -20% | N/A | N/A |
#2 | $6.7M | 43 | 8% | N/A | N/A |
#3 | $34.4M | 222 | -1% | N/A | N/A |
#4 | $5.2M | 67 | 0% | $10M | N/A |
#5 | $2M | 13 | 0% | N/A | N/A |
#6 | $7.5M | 37 | 0% | $51.6M | N/A |
#7 | $0.3M | 2 | -50% | N/A | N/A |
#8 | $4.3M | 21 | -16% | $3.3M | N/A |
#9 | $3.6M | 23 | 0% | N/A | N/A |
#10 | $4.3M | 56 | -8% | $118M | N/A |
What Is Celyad?
Founded in 2007, Celyad s a clinical-stage biopharmaceutical company that leverages unique know-how in taking cell-based therapies from bench to Phase III, as well as the manufacturing and logistical infrastructure for such complex products. Celyad builds it business model on partnering with prominent research institutions such as Dartmouth College, and develops those programs from bench to commercial applications. The Company is currently developing clinical programs in immuno-oncology, testing Natural Killer Receptors T-cells (NKR-T cells) for cancer treatment. A unique approach that has the potential to target and destroy a vast majority of tumor types. Celyad is listed on Euronext Brussels, Euronext Paris and on Nasdaq (CYAD). Immuno-Oncology, Cancer, Immnotherapy, Natural Killer Receptors
keywords:N/A
N/A
Total Funding
489
Number of Employees
$75.8M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
Celyad News
Celyad Oncology SA is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T)...
According to Zacks, "Celyad SA is a biopharmaceutical company. The Company develops and commercializes cell based regenerative therapies to...
Mont-Saint-Guibert, Belgium - Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company plans to participate virtually in the fol ...
Mont-Saint-Guibert, Belgium - Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company plans to participate at the following con ...
MONT-SAINT-GUIBERT, Belgium, May 26, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the company plans to ...
Other Companies in New York
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $138.8M | 489 | 10% | N/A |
#2 | $165M | 489 | 10% | N/A |
#3 | $86.9M | 489 | 3% | $31.5M |
#4 | $139M | 490 | 7% | N/A |
#5 | $110.3M | 490 | N/A | N/A |